We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
-10.3%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$171M
AUM Growth
+$7.86M
Cap. Flow
+$22.3M
Cap. Flow %
13.05%
Top 10 Hldgs %
64.38%
Holding
54
New
21
Increased
3
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
NVS icon
Novartis
NVS
+$14.3M
2
CELG
Celgene Corp
CELG
+$13.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M
4
SHPG
Shire pic
SHPG
+$11.2M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$9.07M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$14.9M
2
PFE icon
Pfizer
PFE
+$10.8M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$6.02M
4
NGNE icon
Neurogene
NGNE
+$4.54M
5
LCI
Lannett Company, Inc.
LCI
+$4.44M

Sector Composition

Rank Sector Weight
1 Healthcare 82.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGNX
51
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-350,000
Closed -$2.22M
FOMX
52
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-125,000
Closed -$1.16M
CLCD
53
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
– –
-100,000
Closed -$3.81M
NDRM
54
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-131,000
Closed -$2.42M
1 2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Nexthera Capital held 54 positions worth $171M, up 4.8% from $163M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Nexthera Capital deployed $22.3M of net new capital in Q4 2016, opening 21 new positions and adding to 3 existing holdings. Its largest new stake was Novartis: 220,968 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 70% a quarter earlier.

On the sell side, the largest reduction was Pfizer, an estimated $10.8M trimmed.

  • Nexthera Capital's largest Q4 2016 buy was Novartis: 220,968 shares worth $14.4M.
  • Nexthera Capital added most to Shire pic in Q4 2016, an estimated $11.2M increase.
  • Nexthera Capital's biggest Q4 2016 reduction was Pfizer, cutting an estimated $10.8M.
  • Nexthera Capital fully exited GSK in Q4 2016, selling an estimated $14.9M.
  • Nexthera Capital's ten largest holdings make up 64% of its $171M portfolio in Q4 2016.
  • Nexthera Capital opened 21 new positions and closed 15 in Q4 2016.
  • Nexthera Capital's portfolio value rose 4.8% quarter-over-quarter to $171M.

Based on Nexthera Capital's 13F filing for Q4 2016, filed 14 Feb 2017.